Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)

Inclusion criteria

• for Case Arm:
• Aged over 18 years.
• Participants confirmed with colorectal adenocarcinoma or advanced adenoma through colonoscopy and pathological examination.
• Provision of informed consent prior to any study specific procedures, sampling, and analyses.
• Inclusion Criteria for Control Arm:
• Individuals of "General risk arm" should meet all the following criteria:
• No history of colorectal adenomas or sessile serrated polyps.
• No history of inflammatory bowel disease (8-10 years ).
• No family history (first-degree relatives) of colorectal cancer.
• Individuals of "High-risk arm" should meet at least one of the following criteria:
• Asia-Pacific Colorectal Screening (APC) score ≥ 3.
• Family history (first-degree relatives) of colorectal cancer.
• History of positive fecal occult blood test.
• Any 2 of the following: chronic diarrhea, chronic constipation, mucous bloody stools, history of psychological stimulation, history of chronic appendicitis or appendectomy, history of chronic biliary disease or cholecystectomy.
• Individuals with inflammatory bowel disease.
• All participants must be confirmed not to have colorectal malignancy or advanced adenomas through colonoscopy.
• Provision of informed consent prior to any study specific procedures, sampling, and analyses.

Exclusion criteria

• History of other malignant tumors (excluding non-melanoma skin cancer).
• Prior or related treatments previously (including colorectal cancer or advanced adenoma surgery, endoscopic treatment, chemotherapy, targeted therapy, immunotherapy, radiation, neoadjuvant therapy, etc.).
• Patients with hereditary colorectal diseases (including Lynch syndrome, familial CRC type X (FCCX), familial adenomatous polyposis (FAP), MUTHY-associated polyposis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis syndrome (JPS), serrated polyposis syndrome (SPS), etc.).
• Usage of anti-tumor drugs such as methotrexate, cyclophosphamide, mercaptopurine, and bendamustine for other diseases within 30 days before blood collection.
• Prior blood transfusion (including blood components) within the past 2 weeks.
• Prior organ transplantation, bone marrow transplantation, or stem cell transplantation.
• Pregnancy women.
• Prior or current anti-infection treatment within 14 days before blood collection.
• Inability to comply with study procedures such as blood collection and related examinations.
• Deemed unsuitable for participation in the clinical trial by the investigator.